IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

MORA, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.778
EU - Europa 1.137
AS - Asia 1.013
SA - Sud America 94
AF - Africa 17
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.042
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.734
IT - Italia 530
SG - Singapore 381
CN - Cina 179
VN - Vietnam 159
UA - Ucraina 137
HK - Hong Kong 109
SE - Svezia 104
TR - Turchia 93
BR - Brasile 77
IE - Irlanda 67
DE - Germania 65
GB - Regno Unito 63
FR - Francia 41
FI - Finlandia 32
RU - Federazione Russa 31
BD - Bangladesh 30
CA - Canada 28
IN - India 17
JP - Giappone 16
MX - Messico 12
PL - Polonia 12
CZ - Repubblica Ceca 10
NL - Olanda 10
ZA - Sudafrica 10
ES - Italia 8
AR - Argentina 6
LT - Lituania 6
PK - Pakistan 6
BE - Belgio 5
AT - Austria 4
CL - Cile 4
KE - Kenya 3
MD - Moldavia 3
SA - Arabia Saudita 3
TH - Thailandia 3
UZ - Uzbekistan 3
VE - Venezuela 3
EC - Ecuador 2
GR - Grecia 2
HU - Ungheria 2
IQ - Iraq 2
KR - Corea 2
KZ - Kazakistan 2
MY - Malesia 2
NG - Nigeria 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
CH - Svizzera 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
EU - Europa 1
GT - Guatemala 1
ID - Indonesia 1
JM - Giamaica 1
LB - Libano 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
TN - Tunisia 1
TW - Taiwan 1
Totale 5.042
Salva come PNG Salva come JPEG
Città #
Milan 375
Fairfield 323
Ashburn 259
Woodbridge 226
Singapore 207
San Jose 173
Houston 165
Chandler 150
Seattle 150
Jacksonville 121
Wilmington 121
Cambridge 116
Ann Arbor 113
Hong Kong 105
Nyköping 77
Dallas 72
Princeton 65
Dublin 64
Izmir 48
The Dalles 44
Boardman 43
Beijing 40
Dearborn 38
Lauterbourg 34
Dong Ket 33
San Diego 31
Hanoi 27
Ho Chi Minh City 25
Los Angeles 23
Rome 23
Como 22
London 21
New York 20
Ogden 20
Helsinki 18
Redmond 18
Orem 16
Santa Clara 15
Kocaeli 13
Munich 13
São Paulo 13
Tokyo 12
Toronto 12
Chicago 11
Warsaw 11
Council Bluffs 10
Atlanta 9
Brno 9
Brooklyn 9
Johannesburg 9
Mexico City 9
Frankfurt am Main 8
Poplar 8
Washington 8
Amsterdam 7
San Francisco 7
Varese 7
Chennai 6
Denver 6
Montreal 6
Ankara 5
Brussels 5
Columbus 5
Dhaka 5
Guangzhou 5
Haiphong 5
Hefei 5
Manchester 5
Rio de Janeiro 5
Shanghai 5
City of London 4
Da Nang 4
Falkenstein 4
Ha Long 4
Hangzhou 4
Jackson 4
Kilburn 4
Kunming 4
Ottawa 4
Redwood City 4
Cavaria con Premezzo 3
Concord 3
Gavirate 3
Islamabad 3
Miami 3
Mumbai 3
Nairobi 3
Nanchang 3
Nanjing 3
Norwalk 3
Nuremberg 3
Phoenix 3
Salt Lake City 3
Stockholm 3
Tashkent 3
Zhengzhou 3
Alvorada 2
Astana 2
Belo Horizonte 2
Biên Hòa 2
Totale 3.790
Salva come PNG Salva come JPEG
Nome #
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts 246
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis 243
Looking for CALR mutations in familial myeloproliferative neoplasms 222
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients 217
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion 217
It is time to change thrombosis risk assessment for PV and ET? 200
Developments in diagnosis and treatment of essential thrombocythemia 198
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients 197
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project 197
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group 197
New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms 170
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation 167
Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis 152
Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia 147
Prognostication in myelofi-brosis 141
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: results of a prospective cohort study of 365 patients 141
Therapy of polycythemia vera: Is it time to change? 135
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project 132
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 126
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 124
Polycythemia vera: From new, modified diagnostic criteria to new therapeutic approaches 121
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients 121
Recurrence of immune thrombocytopenia at the time of SARS-CoV-2 infection 121
Increased plasma levels of lncrnas linc01268, gas5 and malat1 correlate with negative prognostic factors in myelofibrosis 115
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia 114
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses 110
Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma 106
Is there a gender effect in polycythemia vera? 104
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study 103
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 95
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis 94
The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence 85
Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi 82
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 70
Second primary malignancies in ruxolitinib-treated myelofibrosis: Real-world evidence from 219 consecutive patients 69
Direct-acting antivirals in hepatitis C virus-positive mantle cell lymphomas 63
Totale 5.142
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.717
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.717
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202173 0 0 0 0 0 0 0 0 0 0 0 73
2021/2022331 50 16 2 15 11 22 16 21 26 87 19 46
2022/2023473 33 13 75 43 36 102 2 56 75 13 9 16
2023/2024618 91 94 92 115 133 40 7 4 25 2 5 10
2024/2025555 15 3 79 43 23 25 18 54 84 49 42 120
2025/20261.302 106 87 70 229 132 83 245 71 129 82 54 14
Totale 5.142